Bli medlem
Bli medlem

Du är här



Oslo, Norway, 19 August, 2015:
Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on
photodynamic technologies, announces today the appointment of BioSyent Pharma
Inc. as their exclusive distributor for the commercialization of Cysview in
Canada. Cysview®/Hexvix®is Photocure's flagship product to aid in the
diagnosis and management of bladder cancer.

Under the terms of the agreement, Photocure will receive up to USD 1,000,000
in milestone payments for the rights to Cysview in the territory, which
includes USD 650,000 upon signing of the agreement.

BioSyent Pharma will fund all costs related to the launch and
commercialization of Cysview, which was approved by Health Canada in January
2015. The market potential in the territory is estimated to be similar to the
potential in the Nordics, where Photocure commercializes Hexvix with its own
sales team.

Kjetil Hestdal, President&CEO of Photocure, said:
"We are pleased to have secured BioSyent Pharma as our new commercialization
partner in Canada with their market position within urology and their strong
and experienced team. We are happy to report that Hexvix/Cysview
commercialization is progressing well and we continue to expand into new
territories to ensure patients and urologists have access to the most optimal
treatment for the diagnosis and management of bladder cancer."

René Goehrum, President&CEO of BioSyent, said:
"We are delighted to partner with Photocure to commercialize an innovative
product such as Cysview for Canadian patients and health care professionals.
This product has clearly demonstrated that it can improve patient lives.
Furthermore, Cysview fits well with our existing urology business."

For further information, please contact:
President&CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

CFO Erik Dahl
Tel: +47 450 55 000, Email:

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical
company and world leader in photodynamic technology. Based on our unique
proprietary Photocure Technology®platform, Photocure develops and
commercializes highly selective and effective solutions in disease areas with
high unmet medical need, such as bladder cancer, HPV and precancerous
cervical lesions, colorectal cancer and skin conditions. Our aim is to
provide solutions that can improve health outcomes for patients worldwide.
Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about
Photocure is available at

About Hexvix®/Cysview®

Hexvix®/Cysview®(hexaminolevulinate hydro-chloride) is an innovative
breakthrough technology in the diagnosis and management of
non-muscle-invasive bladder cancer. It is designed to selectively target
malignant cells in the bladder and induce fluorescence during a cystoscopic
procedure using a blue-light enabled cystoscope. Using Hexvix®/Cysview®as an
adjunct to standard white-light cystoscopy enables the urologist to better
detect and remove lesions, leading to a reduced risk of recurrence.
Hexvix®/Cysview®is approved in Europe, Canada and the USA.

About BioSyent Pharma Inc

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which
searches the globe to in-license or acquire innovative pharmaceutical
products that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients and supporting
the healthcare professionals that treat them. Once a product of interest has
been found, BioSyent then acquires the exclusive rights to the product and
manages it through the Canadian governmental regulatory approval process.
Once approved, BioSyent markets the product throughout Canada.

All trademarks mentioned in this release are protected by law and are
registered trademarks of Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.